Fortress Biotech, Inc.
FBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | -0.00 | -0.03 | 0.03 |
| FCF Yield | 46.75% | -55.12% | -47.41% | -31.41% |
| EV / EBITDA | -12.17 | -5.32 | -1.15 | -2.79 |
| Quality | ||||
| ROIC | -5.03% | -33.69% | -20.58% | -31.74% |
| Gross Margin | 0.00% | 69.91% | 63.54% | 85.21% |
| Cash Conversion Ratio | -0.69 | 2.36 | 0.79 | 0.49 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.37% | -1.87% | -3.47% | -8.68% |
| Free Cash Flow Growth | 270.98% | -40.88% | -51.57% | 35.65% |
| Safety | ||||
| Net Debt / EBITDA | 2.63 | 0.61 | 0.81 | -0.87 |
| Interest Coverage | 2.48 | -14.48 | -7.96 | -9.19 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.38 | 0.38 | 0.16 |
| Cash Conversion Cycle | 95.06 | -44.87 | -162.30 | -630.28 |